Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

ESMO 2016 conference highlights

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:

Dr Omid Hamid - The Angeles Clinic, California, USA
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )
12 Oct 2016

LUME study of nintedanib finds improved PFS, but no overall survival boost

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
12 Oct 2016

Left versus right sided GI tumour response in the CRYSTAL trial

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
Left versus right sided GI tumour response in the CRYSTAL trial ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
10 Oct 2016

Oncolytic virotherapy using coxsackie virus

Dr Hardev Pandha - University of Surrey, Guildford, UK
Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )
10 Oct 2016

Results of the Activ8 trial of novel immunotherapy motolimod

Dr Ezra Cohen - UC San Diego, San Diego, USA
Results of the Activ8 trial of novel immunotherapy motolimod ( Dr Ezra Cohen - UC San Diego, San Diego, USA )
10 Oct 2016

Lurbinectedin in PARP resistant breast cancer

Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Dr Simon Chowdhury - Guy's Hospital, London, UK
Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
10 Oct 2016

Lurbinectedin in BRCA 1/2 breast cancer

Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016

Olaparib and paclitaxel for 2nd line gastric cancer therapy

Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea
Olaparib and paclitaxel for 2nd line gastric cancer therapy ( Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea )
10 Oct 2016

Comment: Ipilimumab in high risk stage III melanoma

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Ipilimumab in high risk stage III melanoma ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation